{"Clinical Trial ID": "NCT00357110", "Intervention": ["INTERVENTION 1:", "-Fulvestant + Anastrozole", "Fulvestrant 500 mg + anastrozole 1 mg", "INTERVENTION 2:", "Anastrozole", "Anastrozole 1 mg"], "Eligibility": ["Incorporation criteria:", "\u2022 Menopausal women with early breast cancer of positive hormonal receptors and positive immunocytochemical cell result Tumor Disseminated following bone marrow aspiration prior to randomization", "- Exclusion criteria:", "Inflammatory and/or metastatic breast cancer.", "- current or previous malignancy in the previous five years (other than breast cancer or non-melanoma skin cancer or in situ cervical cancer adequately treated).", "History of haemorrhagic diathesis."], "Results": ["Performance measures:", "* Patients without event at 12 months (where event = death (of any cause), tumour cells disseminated positive at 12 months or recurrence of clinical diseases)", "Number of patients without event", "Time limit: 12 months after randomisation", "Results 1:", "Title of the arm/group: Fulvestant + Anastrozole", "Description of the arm/group: flulvestrant 500 mg + anastrozole 1 mg", "Total number of participants analysed: 6", "Type of measurement: Number", "Unit of measure: Participants 6", "Results 2:", "Title of the arm/group: Anastrozole", "Description of the arm/group: anastrozole 1 mg", "Total number of participants analysed: 7", "Type of measurement: Number", "Unit of measure: Participants 7"], "Adverse Events": ["Undesirable Events 1:", "Total: 1/6 (16.67%)", "- Goiter 0/6 (0.00 %)", "Hemorrhoid operation 0/6 (0.00 %)", "Sciatica 0/6 (0.00 %)", "- Renal failure 0/6 (0.00 %)", "Varicose Vein 1/6 (16.67%)", "Adverse Events 2:", "Total: 2/7 (28.57 per cent)", "1/7 taste (14.29 per cent)", "Hemorrhoid operation 1/7 (14.29%)", "Sciatica 1/7 (14.29%)", "Renal defect 1/7 (14.29%)", "Varicose Vein 0/7 (0.00 %)"]}